9780231171182-0231171188-FDA in the Twenty-First Century: The Challenges of Regulating Drugs and New Technologies

FDA in the Twenty-First Century: The Challenges of Regulating Drugs and New Technologies

FREE US shipping
Buy

From $26.25

Book details

Summary

FDA in the Twenty-First Century: The Challenges of Regulating Drugs and New Technologies (ISBN-13: 9780231171182 and ISBN-10: 0231171188), written by authors I. Glenn Cohen, Holly Fernandez Lynch, was published by Columbia University Press in 2015. With an overall rating of 3.6 stars, it's a notable title among other Pharmaceutical & Biotechnology (Industries, Education & Reference, Government & Business, Processes & Infrastructure, Safety & First Aid, Administrative Law, Health Law, Health & Medical Law, Biotechnology, Biological Sciences) books. You can easily purchase or rent FDA in the Twenty-First Century: The Challenges of Regulating Drugs and New Technologies (Hardcover) from BooksRun, along with many other new and used Pharmaceutical & Biotechnology books and textbooks. And, if you're looking to sell your copy, our current buyback offer is $1.86.

Description

In its decades-long effort to assure the safety, efficacy, and security of medicines and other products, the Food and Drug Administration has struggled with issues of funding, proper associations with industry, and the balance between consumer choice and consumer protection. Today, these challenges are compounded by the pressures of globalization, the introduction of novel technologies, and fast-evolving threats to public health. With essays by leading scholars and government and private-industry experts, FDA in the Twenty-First Century addresses perennial and new problems and the improvements the agency can make to better serve the public good.

The collection features essays on effective regulation in an era of globalization, consumer empowerment, and comparative effectiveness, as well as questions of data transparency, conflicts of interest, industry responsibility, and innovation policy, all with an emphasis on pharmaceuticals. The book also intervenes in the debate over off-label drug marketing and the proper role of the FDA before and after a drug goes on the market. Dealing honestly and thoroughly with the FDA's successes and failures, these essays rethink the structure, function, and future of the agency and the effect policy innovations may have on regulatory institutions abroad.

Rate this book Rate this book

We would LOVE it if you could help us and other readers by reviewing the book